A Collaborative Approach to Treating Hormone- Refractory Prostate cancer.

CONFERENCES & conventions; AMERICAN Urological Association; MALE reproductive organ cancer; CANCER treatment; CANCER chemotherapy; DRUG therapy; ANTINEOPLASTIC agents

Information about several papers discussed at the Northeastern Section of the American Urological Association 2005 Annual Meeting which focuses on new approaches to hormone-refractory prostate cancer treatment is presented. It has been emphasized that there exist several therapeutic options in managing prostate cancer including the treatment with a chemotherapy drug Docetaxel that provides patients with an increased chance of survival compared to other traditional therapy.